Physician profile
Richard Forrest Wright
NPI 1770580151
$1,694,494.07
in general payments reported to CMS, 2019-2025
49 companies · $321K in 2025
The $321K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298K · 2020: $134K · 2021: $106K · 2022: $166K · 2023: $278K · 2024: $391K · 2025: $321K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $760K · Travel and Lodging: $92K · Consulting Fee: $77K · Honoraria: $35K · Food and Beverage: $26K · Education: $51.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $759,864.44 |
| Travel and Lodging | $92,244.29 |
| Consulting Fee | $76,571.02 |
| Honoraria | $35,280.00 |
| Food and Beverage | $25,966.15 |
| Education | $51.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $417,687.67 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $346,769.71 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300,713.40 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $149,192.95 | 2019-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $137,939.01 | 2019-2025 | Leqvio |
| Astrazeneca Pharmaceuticals Lp | $96,172.10 | 2019-2025 | Wainua, Farxiga |
| Akcea Therapeutics, INC. | $84,004.42 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $39,212.16 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $33,878.17 | 2023-2025 | |
| Lilly USA, LLC | $30,367.47 | 2020-2025 | Jardiance, Mounjaro |
| Bridgebio Pharma, INC. | $30,142.99 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $8,279.11 | 2019 | |
| Pfizer INC. | $7,858.28 | 2019-2025 | |
| Boston Scientific Corporation | $4,340.54 | 2019-2024 | Bodyguardian, Watchman Access System |
| Eli Lilly and Company | $3,575.00 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.